NK Cell Therapy Trials for Relapsed AML Explore Immune Attack on Blood Cancer
A Phase 1/2 trial tests donor NK cells with chemotherapy conditioning to fight relapsed or refractory acute myeloid leukemia.
Summary
Acute myeloid leukemia (AML) that returns or fails to respond to treatment is one of the most lethal blood cancers, with very limited options for older adults. This terminated Phase 1/2 trial from Radboud University Medical Center investigated whether natural killer (NK) cells grown outside the body from umbilical cord blood could be infused into AML patients after non-myeloablative chemotherapy to trigger an immune attack on the cancer. Some patients also received IL-2 to help the NK cells survive and expand in the body. The trial was terminated before completion, so full efficacy data are unavailable. The approach represents a promising frontier in cellular immunotherapy — using the innate immune system to target cancer without the toxicity of full bone marrow ablation.
Detailed Summary
Acute myeloid leukemia is an aggressive blood cancer whose prognosis becomes extremely poor once it relapses or proves refractory to standard therapy. This is especially relevant in older adults, who bear the highest disease burden and tolerate intensive treatment least well. Novel immune-based approaches are urgently needed.
This Phase 1/2 clinical trial (NCT04347616), sponsored by Radboud University Medical Center, investigated allogeneic natural killer (NK) cell therapy as a treatment strategy for relapsed or refractory AML in adult patients. NK cells — key effectors of the innate immune system — can recognize and kill cancer cells without the need for prior sensitization, making them attractive candidates for adoptive cell therapy. The trial used NK cells generated ex vivo from umbilical cord blood (UCB-NK), administered after a non-myeloablative conditioning chemotherapy regimen designed to create immune space without fully destroying the patient's bone marrow. A subset of patients also received IL-2 cytokine support to promote NK cell persistence and activity in vivo.
The trial was registered in 2020 and has since been terminated. No efficacy results are publicly available from the abstract, and the reasons for termination are not specified. Phase 1 components were likely focused on safety, dosing, and feasibility.
The clinical implications remain significant even given early termination. UCB-NK cell therapy is part of a broader wave of off-the-shelf cellular immunotherapy — approaches that could eventually provide readily available, scalable immune treatments for blood cancers in older populations who cannot tolerate stem cell transplantation.
Key caveats: the trial was terminated, so no conclusion about efficacy can be drawn. The summary is based on the abstract only, and reasons for termination, patient numbers, and safety outcomes are not publicly disclosed.
Key Findings
- Phase 1/2 trial tested cord-blood-derived NK cells plus chemotherapy conditioning in adults with relapsed or refractory AML.
- IL-2 cytokine support was included for some patients to enhance NK cell survival and expansion in vivo.
- Non-myeloablative conditioning was chosen to reduce toxicity compared to full bone marrow ablation protocols.
- The trial was terminated before completion; no efficacy outcomes are publicly available.
- UCB-NK cell therapy represents an off-the-shelf cellular immunotherapy approach relevant to older, treatment-ineligible AML patients.
Methodology
This was a Phase 1/2 interventional clinical trial enrolling adult patients with relapsed or refractory AML. Patients received ex vivo-expanded allogeneic umbilical cord blood NK cells following non-myeloablative conditioning chemotherapy, with or without subsequent IL-2 support. The trial was sponsored by Radboud University Medical Center and has been terminated.
Study Limitations
The trial was terminated before completion, and no efficacy or safety outcomes are available in the public abstract. The summary is based on the abstract only, with no access to full protocol, enrollment numbers, or reasons for termination. The absence of results means no conclusions about clinical benefit can be drawn.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: